Allison C. Swartz is seeking to sell 3,903 Progyny common shares valued at approximately $101,868.30. For investors, the notice identifies the proposed sale, the stock’s approximate value and records showing the shares associated with restricted-stock vesting and compensation entries.
Key Highlights
- The proposed transaction covers 3,903 Progyny common shares with an estimated value of $101,868.30.
- Allison C. Swartz is identified as an officer in the notice.
- The listed vesting amounts are 2,398 shares on Aug. 28, 1,047 on Sep. 3 and 458 on Sep. 4.
Allison C. Swartz is seeking to sell 3,903 common shares of Progyny (NASDAQ: PGNY) valued at approximately $101,868.30.
$101,868.30 Common-Stock Sale Detailed
The notice identifies Progyny’s address as 1359 Broadway, 2nd Floor, New York, New York 10018, and records the security as common stock traded on Nasdaq. The underlying entries list 2,398 shares linked to restricted-stock vesting dated Aug. 28, 1,047 shares tied to vesting dated Sep. 3 and 458 shares connected with vesting dated Sep. 4. Each entry is marked with the issuer designation, while compensation is also shown in the transaction details. The record carries Sep. 23 as the transaction date. Jared Cook signed on Jun. 25 as Fidelity Brokerage Services LLC’s duly authorized representative and attorney-in-fact for Allison C. Swartz.
FAQs
Q: How many Progyny shares does Allison Swartz plan to sell?
A: Allison C. Swartz plans to sell 3,903 Progyny common shares. The proposed transaction values those shares at approximately $101,868.30.
Q: What is the estimated value of the Progyny share sale?
A: The Progyny share sale is valued at approximately $101,868.30. The securities involved are common shares associated with Allison C. Swartz.
Q: When were the shares connected to restricted-stock vesting?
A: The listed vesting dates are Aug. 28, Sep. 3 and Sep. 4. The corresponding amounts are 2,398 shares, 1,047 shares and 458 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.